2025 Axol Bioscience eBook
Explore our ongoing work towards building better human disease models in this comprehensive eBook, where we guide you through our missions and projects alongside a supporting directory of our products and services.
Learn about our ongoing work with human iPSCs
There is a clear and increasingly urgent need for better human disease models in drug discovery. Thankfully, the industry is becoming increasingly aware of the pivotal role human iPSCs will play in physiologically-relevant in vitro models to develop better, safer therapies.
With over a decade of experience in the iPSC industry, we’re excited to build on the momentum of key drivers like the FDA Modernization Act 2.0 and ISSCR Standards Document 2023. We’ve therefore collated our story, projects, and comprehensive range of offerings into this eBook.
You can find information about our patients and healthy donor-derived human iPSCs (axoLines) and axoCells iPSC-derived neuronal and cardiac cells, our suite of custom lab axoServices and how we can apply our iPSC expertise to collaboratively build robust axoModels for compound screening.
Ultimately, we’re all working towards the same goal: better, safer therapies for patients worldwide.
Highlights
Inside the 2025 Axol Bioscience eBook , you’ll find:
- The key opportunities, needs, and missions that drive our ongoing work towards better human disease models
- A directory of our iPSC offerings including high-quality, consistent iPSCs and endpoint cells
- Our library of patient and control-derived cells from specific diseases like Alzheimer’s Disease, Parkinson’s Disease and ALS
- A complete description of our custom lab services including reprogramming, differentiation, gene editing, compound screening and custom assays
- General information on our capabilities, expertise, and approach to collaboration
| Chapter | Description |
| Introduction | Take a look into the key drivers behind the desperate need for better, more human-relevant disease models in drug discovery |
| Lines and Cells | Explore the building blocks of effective, human-relevant models: patient and healthy control-derived iPSC axoLines (across a range of therapy areas) and high-quality, consistent endpoint axoCells derived from iPSCs. |
| Services and Assays | Understand more about how we’re leveraging our iPSC expertise and removing the technical burden across our comprehensive suite of custom lab axoServices including reprogramming, differentiation, gene editing, compound screening and custom assays |
| Models and the future | Bringing it all together, explore how we’re tackling the need for better model systems in drug discovery by collaboration with biopharma organizations to power advanced in vitro axoModels with high-quality iPSCs. |